Springfield: College offers CNA program
Springfield Technical Community College is offering a Certified Nurse Aide (CNA) Plus Program, and personal trainer national certification.
Classes for the CNA program begin on Monday, Feb. 24. They will be held from 9 a.m. to 2:30 p.m. Monday through Thursday. Applications are now being accepted. Space is limited.
Classes for personal trainer national certification take place from 9 a.m. to 4 p.m. Saturdays between March 8 and April 12. Space in all programs is limited and preregistration is required.
Information: (413) 755-4502, www.stcc.edu/wd.
Pittsfield: Local attorney to speak at Zucchini’s
Attorney Kenneth P. Ferris of the Pittsfield law firm Hashim & Spinola will speak when the Berkshire Association for Paralegals and Legal Secretaries meets on Wednesday, Feb. 12, at Zucchini’s Restaurant.
Networking/socializing takes place from 5:30 to 6 p.m., followed by dinner at 6:15 and the speaking program. Ferris will be speaking on foreclosures. Those with foreclosure questions for Ferris can mail them to Christine Shea at email@example.com. The cost is $25 per person for members, and $30 per person for nonmembers. Dinner menu descriptions are available at zucchinisrestaurant.com. Payment and meal choice should be mailed to: Christine Shea, Treasurer, c/o BAPLS, P.
Those with food allergies or concerns can call Zucchini’s at (413) 442-2777.
Pittsfield: Nuclea signs 2 development deals
Nuclea Biotechnologies has signed two development deals that will allow the firm to include new laboratory-developed tests in its expanded service offerings.
The deals that Nuclea signed with AccuGenomics Inc. and Nuvera Biosciences Inc. will including validating two new assays in the treatment of chronic myeloid leukemia (CML) and breast cancer.
They include the manufacturing and selling of kits for one assay, and offering both assays in their CLIA laboratory.
The agreement with AccuGenomics, Inc. will soon lead to more effective treatments for those diagnosed with CML.
The deal with Nuvera centers on the co-development of their gene-based breast cancer assay which can predict patient responsiveness to taxane chemotherapy and endocrine therapy.
Nuclea will conduct the development of the assay, along with securing CLIA validation, beginning in February.